PubMed Journals Articles About "European Randomized Study Screening Prostate Cancer ERSPC" RSS

16:23 EDT 19th March 2018 | BioPortfolio

European Randomized Study Screening Prostate Cancer ERSPC PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest European Randomized Study Screening Prostate Cancer ERSPC articles that have been published worldwide.

More Information about "European Randomized Study Screening Prostate Cancer ERSPC" on BioPortfolio

We have published hundreds of European Randomized Study Screening Prostate Cancer ERSPC news stories on BioPortfolio along with dozens of European Randomized Study Screening Prostate Cancer ERSPC Clinical Trials and PubMed Articles about European Randomized Study Screening Prostate Cancer ERSPC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of European Randomized Study Screening Prostate Cancer ERSPC Companies in our database. You can also find out about relevant European Randomized Study Screening Prostate Cancer ERSPC Drugs and Medications on this site too.

Showing "European Randomized Study Screening Prostate Cancer ERSPC" PubMed Articles 1–25 of 77,000+

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

The ERSPC (European Randomized Study of Screening for Prostate Cancer) found that screening reduced prostate cancer mortality, but the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found no reduction.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio, 0.79; 95% confidence interval, 0.69-0.91). The US Prostate, Lung, Colorectal, and Ovarian (PLCO) trial indicated no such reduction but had a wide 95% CI (rate ratio for prostate cancer mortality, 1.09; 95% CI, 0.87-1.36). Standard meta-analyses are unable to account for key differences between the trials that can impac...

Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.

Few empirical analyses of the impact of organised prostate cancer (PCa) screening on healthcare costs exist, despite cost-related information often being considered as a prerequisite to informed screening decisions. Therefore, we estimate the differences in register-based costs of publicly funded healthcare in the two arms of the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) after 20 years.

Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.

Prostate cancer is the most commonly diagnosed non-skin cancer in men. Screening for prostate cancer is widely accepted; however concerns regarding the harms outweighing the benefits of screening exist. Although patient's play a pivotal role in the decision making process, men may not be aware of the controversies regarding prostate cancer screening. Therefore we aimed to describe men's attitudes, beliefs and experiences of prostate cancer screening.

Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.

Policy decisions about prostate cancer screening require data on the natural history of histological cancers and the resulting impact of screening. However, the gold standard procedure required to identify true positive histological cancer is a full autopsy of the gland which is not possible in screening studies, leading to verification bias. We aim to estimate the sensitivity of a prostate cancer screening round (PSA result to diagnosis) relative to histological cancer.

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.

Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.

To identify the prognostic factors of prostate cancer death among patients enrolled in a Finnish prostate cancer screening trial.

Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.

The common tool for diagnosing prostate cancer is prostate-specific antigen (PSA), but the high sensitivity and low specificity of PSA testing are the problems in clinical practice. There are no proper guidelines to investigate the suspected prostate cancer in the Cayman Islands. We correlated PSA levels with the incidence of prostate cancers by tissue diagnosis and proposed logical protocol for prostate screening by using PSA test in this small population.

Are there regional tendencies toward controversial screening practices? A study of prostate and breast cancer screening in a Medicare population.

Prostate and breast cancer screening in older patients continue to be controversial. Balancing the desire for early detection with avoidance of over-diagnosis has led to competing and contradictory guidelines for both practices. Despite similarities, it is not known how these screening practices are related at the regional level. In this study, we examined how screening PSA and mammography are related within healthcare regions, and, to better understand what may be driving these practices, whether they are ...

Prostate-specific antigen screening: An update of physician beliefs and practices.

PSA testing for early detection of prostate cancer decreased dramatically following the 2012 PSA screening recommendation against routine screening of asymptomatic men. In an assessment of the screening behaviors of primary care providers, the majority (61%) of family medicine and internal medicine practitioners who responded to a 2016 DocStyles online survey (608 of 1003) recommended prostate-specific antigen (PSA) testing based on individual risk or other factors, rather than routinely screening all men f...

The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data.

Symptoms of terminal cancer have previously been reported as undertreated. The aim of this study was to assess the use of palliative medications before death from prostate cancer.

Risk of early-onset prostate cancer associated with occupation in the Nordic countries.

Early-onset prostate cancer is often more aggressive and may have a different aetiology than later-onset prostate cancer, but has been relatively little studied to date. We evaluated occupation in relation to early- and later-onset prostate cancer in a large pooled study.

Long-term outcome of a single intervention Population based Prostate Cancer Screening Study.

To evaluate long term effect of screening for prostate cancer.

Implementation of a 5-Minute Magnetic Resonance Imaging Screening Protocol for Prostate Cancer in Men With Elevated Prostate-Specific Antigen Before Biopsy.

The aims of this study were to establish a 5-minute magnetic resonance (MR) screening protocol for prostate cancer in men before biopsy and to evaluate effects on Prostate Imaging Reporting and Data System (PI-RADS) V2 scoring in comparison to a conventional, fully diagnostic multiparametric MR imaging (mpMRI) approach.

Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.

The diagnosis and management of prostate cancer have substantially changed over the last 3 decades. Serum prostate-specific antigen (PSA) was adopted for screening in the 1990s after it was found to be a sensitive indicator of disease. Because of a lack of specificity for significant disease, indiscriminate PSA testing led to overdiagnosis and overtreatment. Several biomarkers have been developed that are superior to PSA in stratifying a man's risk for harboring potentially lethal prostate cancer.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

This corrects the article DOI: 10.1038/bjc.2017.429.

Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.

Racial disparities in prostate cancer survival (PCS) narrowed during the prostate-specific antigen (PSA) era, suggesting that screening may induce more equitable outcomes. However, the effects of lead time and overdiagnosis can inflate survival even without real screening benefit.

Knowledge, Attitudes and Perceptions of Prostate Cancer among Male Staff of the University of Nigeria

Prostate cancer is the number one cancer in males in Africa, both in terms of incidence and mortality, accounting for 40,000 (13%) male cancers and 28,000 (11.3%) male cancer-associated deaths. In the developed world, the probability of being diagnosed with cancer is more than twice as high as in developing countries. In developing countries, most cancer victims are diagnosed at late stage, with incurable tumors, pointing to the need for education schemes and better detection programs. This study assessed k...

Beyond the PSA test: How to better stratify a patient's risk of prostate cancer.

The primary method of screening for and detecting prostate cancer is the prostate-specific antigen (PSA) test. Although this test is very prostate-specific, it is not cancer-specific; conditions other than prostate cancer can cause an elevated PSA. Many efforts have been made to discover more specific tests and methods beyond the PSA. This article describes several literature-supported tests and methods to better stratify a man's risk of having prostate cancer.

Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice.

This study serves as an update of prostate cancer screening practices among family physicians in Ontario, Canada. Since this population was first surveyed in 2010, the Canadian Task Force on Preventive Health Care (CTFPHC) and the United States Preventive Services Task Force (USPSTF) released recommendations against prostate cancer screening.

Prostate cancer: Updates on current strategies for screening, diagnosis and clinical implications of treatment modalities.

Prostate cancer is the most common cancer in men by way of diagnosis, and a leading cause of cancer-related deaths. Early detection and intervention remains key to its optimum clinical management. This review provides the most updated information on the recent methods of prostate cancer screening, imaging and treatment modalities. Wherever possible, clinical trial data has been supplemented to provide a comprehensive overview of current prostate cancer research and development. Considering the recent succes...

Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.

Because of the recent grade C draft recommendation by the US Preventive Services Task Force (USPSTF) for prostate cancer screening between the ages of 55 and 69 years, there is a need to determine whether this could be cost-effective in a US population setting.

c-Met, CREB1 and EGFR are involved in miR-493-5p inhibition of EMT via AKT/GSK-3β/Snail signaling in prostate cancer.

miR-493-5p downregulation has emerged as a critical player in cancer progression yet, the underlying mechanisms of miR-493-5p expression pattern and its function in prostate cancer remains to be elucidated. Here, we illustrate that miR-493-5p is frequently downregulated in prostate cancer, at least partially due to altered DNA methylation. miR-493-5p functions as a tumor suppressor in prostate cancer cells. c-Met, CREB1 and EGFR are downstream target genes of miR-493-5p. miR-493-5p inhibits EMT via AKT/GSK-...

A qualitative meta-synthesis examining the role of women in African American men's prostate cancer screening and treatment decision-making.

Being an African American man is a risk factor for prostate cancer and there is little consensus about the utility of screening, early detection, and the efficacy of treatment for the disease. In this context, this systematic review examines the roles women, particularly wives, play in African American men's prostate cancer screening and treatment decision-making.

Contemporary Incidence & Outcomes of Prostate Cancer Lymph Node Metastases.

The incidence of localized prostate cancer has declined with shifts in prostate cancer screening. While recent population-based studies demonstrate a stable incidence of loco-regional prostate cancer, this categorized organ-confined, extra-prostatic and lymph node positive disease together. The contemporary incidence of prostate cancer with pelvic lymph node metastases (PLNM) however, remains unknown.

Quick Search